nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—TNF—acquired immunodeficiency syndrome	0.4	1	CbGaD
Pomalidomide—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.0285	0.0706	CbGbCtD
Pomalidomide—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.0268	0.0664	CbGbCtD
Pomalidomide—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.0268	0.0664	CbGbCtD
Pomalidomide—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.0243	0.06	CbGbCtD
Pomalidomide—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0235	0.0581	CbGbCtD
Pomalidomide—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0212	0.0525	CbGbCtD
Pomalidomide—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.0203	0.0503	CbGbCtD
Pomalidomide—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.0184	0.0455	CbGbCtD
Pomalidomide—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0183	0.0453	CbGbCtD
Pomalidomide—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.0178	0.044	CbGbCtD
Pomalidomide—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.0161	0.0398	CbGbCtD
Pomalidomide—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.0161	0.0398	CbGbCtD
Pomalidomide—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.0154	0.0382	CbGbCtD
Pomalidomide—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0149	0.037	CbGbCtD
Pomalidomide—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0141	0.0348	CbGbCtD
Pomalidomide—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0141	0.0348	CbGbCtD
Pomalidomide—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0127	0.0315	CbGbCtD
Pomalidomide—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0127	0.0315	CbGbCtD
Pomalidomide—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.0119	0.0295	CbGbCtD
Pomalidomide—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.011	0.0272	CbGbCtD
Pomalidomide—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0107	0.0264	CbGbCtD
Pomalidomide—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00963	0.0238	CbGbCtD
Pomalidomide—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00963	0.0238	CbGbCtD
Pomalidomide—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00923	0.0229	CbGbCtD
Pomalidomide—TNF—blood—acquired immunodeficiency syndrome	0.00251	0.0783	CbGeAlD
Pomalidomide—TNF—vagina—acquired immunodeficiency syndrome	0.00233	0.0726	CbGeAlD
Pomalidomide—Thalidomide—TNF—acquired immunodeficiency syndrome	0.00187	1	CrCbGaD
Pomalidomide—CRBN—retina—acquired immunodeficiency syndrome	0.00179	0.0559	CbGeAlD
Pomalidomide—TNF—lymph node—acquired immunodeficiency syndrome	0.0015	0.0469	CbGeAlD
Pomalidomide—TNF—EV release from cardiac cells and their functional effects—CXCL12—acquired immunodeficiency syndrome	0.0015	0.0842	CbGpPWpGaD
Pomalidomide—CRBN—lymphoid tissue—acquired immunodeficiency syndrome	0.00127	0.0398	CbGeAlD
Pomalidomide—CRBN—digestive system—acquired immunodeficiency syndrome	0.00126	0.0393	CbGeAlD
Pomalidomide—CRBN—blood—acquired immunodeficiency syndrome	0.0012	0.0374	CbGeAlD
Pomalidomide—CRBN—bone marrow—acquired immunodeficiency syndrome	0.00116	0.0362	CbGeAlD
Pomalidomide—CRBN—spinal cord—acquired immunodeficiency syndrome	0.00116	0.0361	CbGeAlD
Pomalidomide—CRBN—vagina—acquired immunodeficiency syndrome	0.00111	0.0347	CbGeAlD
Pomalidomide—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.00108	0.0336	CbGeAlD
Pomalidomide—CRBN—lung—acquired immunodeficiency syndrome	0.00105	0.0328	CbGeAlD
Pomalidomide—PTGS2—endothelium—acquired immunodeficiency syndrome	0.001	0.0313	CbGeAlD
Pomalidomide—CRBN—nervous system—acquired immunodeficiency syndrome	0.000974	0.0304	CbGeAlD
Pomalidomide—CRBN—central nervous system—acquired immunodeficiency syndrome	0.000937	0.0292	CbGeAlD
Pomalidomide—PTGS2—blood plasma—acquired immunodeficiency syndrome	0.000891	0.0278	CbGeAlD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL15—acquired immunodeficiency syndrome	0.000879	0.0492	CbGpPWpGaD
Pomalidomide—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000779	0.0243	CbGeAlD
Pomalidomide—CRBN—brain—acquired immunodeficiency syndrome	0.000744	0.0232	CbGeAlD
Pomalidomide—CRBN—lymph node—acquired immunodeficiency syndrome	0.000719	0.0224	CbGeAlD
Pomalidomide—TNF—FAS pathway and Stress induction of HSP regulation—ACTG1—acquired immunodeficiency syndrome	0.000592	0.0331	CbGpPWpGaD
Pomalidomide—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000551	0.0172	CbGeAlD
Pomalidomide—TNF—EBV LMP1 signaling—CCL5—acquired immunodeficiency syndrome	0.000442	0.0247	CbGpPWpGaD
Pomalidomide—PTGS2—skin of body—acquired immunodeficiency syndrome	0.000429	0.0134	CbGeAlD
Pomalidomide—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000414	0.0129	CbGeAlD
Pomalidomide—CYP1A2—blood—acquired immunodeficiency syndrome	0.000394	0.0123	CbGeAlD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL10—acquired immunodeficiency syndrome	0.000387	0.0217	CbGpPWpGaD
Pomalidomide—TNF—Cytokines and Inflammatory Response—CSF2—acquired immunodeficiency syndrome	0.000383	0.0214	CbGpPWpGaD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL4—acquired immunodeficiency syndrome	0.000376	0.0211	CbGpPWpGaD
Pomalidomide—PTGS2—lymphoid tissue—acquired immunodeficiency syndrome	0.000347	0.0108	CbGeAlD
Pomalidomide—CYP1A2—lung—acquired immunodeficiency syndrome	0.000346	0.0108	CbGeAlD
Pomalidomide—PTGS2—digestive system—acquired immunodeficiency syndrome	0.000343	0.0107	CbGeAlD
Pomalidomide—PTGS2—blood—acquired immunodeficiency syndrome	0.000327	0.0102	CbGeAlD
Pomalidomide—PTGS2—bone marrow—acquired immunodeficiency syndrome	0.000316	0.00986	CbGeAlD
Pomalidomide—PTGS2—spinal cord—acquired immunodeficiency syndrome	0.000315	0.00982	CbGeAlD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—CCL4—acquired immunodeficiency syndrome	0.000304	0.017	CbGpPWpGaD
Pomalidomide—PTGS2—vagina—acquired immunodeficiency syndrome	0.000303	0.00945	CbGeAlD
Pomalidomide—ABCB1—retina—acquired immunodeficiency syndrome	0.000302	0.00942	CbGeAlD
Pomalidomide—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.0003	0.00935	CbGeAlD
Pomalidomide—PTGS2—lung—acquired immunodeficiency syndrome	0.000286	0.00893	CbGeAlD
Pomalidomide—CYP3A4—blood—acquired immunodeficiency syndrome	0.000285	0.0089	CbGeAlD
Pomalidomide—TNF—TWEAK Signaling Pathway—CCL5—acquired immunodeficiency syndrome	0.000273	0.0153	CbGpPWpGaD
Pomalidomide—PTGS2—nervous system—acquired immunodeficiency syndrome	0.000265	0.00827	CbGeAlD
Pomalidomide—PTGS2—central nervous system—acquired immunodeficiency syndrome	0.000255	0.00796	CbGeAlD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—IFNA1—acquired immunodeficiency syndrome	0.000239	0.0134	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—CCL4—acquired immunodeficiency syndrome	0.000237	0.0133	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—acquired immunodeficiency syndrome	0.000236	0.0132	CbGpPWpGaD
Pomalidomide—TNF—IL27-mediated signaling events—IFNG—acquired immunodeficiency syndrome	0.000235	0.0131	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CSF2—acquired immunodeficiency syndrome	0.000234	0.0131	CbGpPWpGaD
Pomalidomide—TNF—Vitamin B12 Metabolism—CCL5—acquired immunodeficiency syndrome	0.000234	0.0131	CbGpPWpGaD
Pomalidomide—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000232	0.00723	CbGeAlD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—acquired immunodeficiency syndrome	0.00023	0.0129	CbGpPWpGaD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IFNG—acquired immunodeficiency syndrome	0.000228	0.0127	CbGpPWpGaD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—acquired immunodeficiency syndrome	0.000226	0.0127	CbGpPWpGaD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—CSF2—acquired immunodeficiency syndrome	0.000223	0.0125	CbGpPWpGaD
Pomalidomide—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000223	0.00696	CbGeAlD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL4—acquired immunodeficiency syndrome	0.00022	0.0123	CbGpPWpGaD
Pomalidomide—TNF—Cytokines and Inflammatory Response—CD4—acquired immunodeficiency syndrome	0.00022	0.0123	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—CXCL12—acquired immunodeficiency syndrome	0.000216	0.0121	CbGpPWpGaD
Pomalidomide—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000215	0.0067	CbGeAlD
Pomalidomide—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000212	0.00662	CbGeAlD
Pomalidomide—TNF—IL27-mediated signaling events—IL2—acquired immunodeficiency syndrome	0.000208	0.0117	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—CCL3—acquired immunodeficiency syndrome	0.000207	0.0116	CbGpPWpGaD
Pomalidomide—PTGS2—brain—acquired immunodeficiency syndrome	0.000203	0.00632	CbGeAlD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL2—acquired immunodeficiency syndrome	0.000202	0.0113	CbGpPWpGaD
Pomalidomide—ABCB1—blood—acquired immunodeficiency syndrome	0.000202	0.0063	CbGeAlD
Pomalidomide—PTGS2—lymph node—acquired immunodeficiency syndrome	0.000196	0.00611	CbGeAlD
Pomalidomide—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000195	0.0061	CbGeAlD
Pomalidomide—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000195	0.00607	CbGeAlD
Pomalidomide—ABCB1—vagina—acquired immunodeficiency syndrome	0.000187	0.00584	CbGeAlD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—CD8A—acquired immunodeficiency syndrome	0.000187	0.0105	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—MBL2—acquired immunodeficiency syndrome	0.000187	0.0105	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—IL4—acquired immunodeficiency syndrome	0.000184	0.0103	CbGpPWpGaD
Pomalidomide—ABCB1—lung—acquired immunodeficiency syndrome	0.000177	0.00553	CbGeAlD
Pomalidomide—TNF—IL23-mediated signaling events—IFNG—acquired immunodeficiency syndrome	0.000177	0.0099	CbGpPWpGaD
Pomalidomide—TNF—IL23-mediated signaling events—CD4—acquired immunodeficiency syndrome	0.000171	0.00956	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—IFNA1—acquired immunodeficiency syndrome	0.000169	0.00945	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—CCR2—acquired immunodeficiency syndrome	0.000167	0.00934	CbGpPWpGaD
Pomalidomide—ABCB1—nervous system—acquired immunodeficiency syndrome	0.000164	0.00512	CbGeAlD
Pomalidomide—TNF—Allograft Rejection—CD40LG—acquired immunodeficiency syndrome	0.000164	0.00918	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—IL10—acquired immunodeficiency syndrome	0.000164	0.00918	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—CCL3—acquired immunodeficiency syndrome	0.000162	0.00906	CbGpPWpGaD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	0.000161	0.00112	CcSEcCtD
Pomalidomide—Body temperature increased—Stavudine—acquired immunodeficiency syndrome	0.000161	0.00112	CcSEcCtD
Pomalidomide—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.000161	0.00111	CcSEcCtD
Pomalidomide—Mediastinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.00016	0.00111	CcSEcCtD
Pomalidomide—Insomnia—Zidovudine—acquired immunodeficiency syndrome	0.00016	0.00111	CcSEcCtD
Pomalidomide—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.00016	0.00111	CcSEcCtD
Pomalidomide—Chills—Lamivudine—acquired immunodeficiency syndrome	0.00016	0.00111	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—IL4—acquired immunodeficiency syndrome	0.000159	0.00893	CbGpPWpGaD
Pomalidomide—Hyperhidrosis—Indinavir—acquired immunodeficiency syndrome	0.000159	0.00111	CcSEcCtD
Pomalidomide—Cough—Delavirdine—acquired immunodeficiency syndrome	0.000159	0.0011	CcSEcCtD
Pomalidomide—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	0.000159	0.0011	CcSEcCtD
Pomalidomide—Tremor—Ritonavir—acquired immunodeficiency syndrome	0.000158	0.0011	CcSEcCtD
Pomalidomide—Dyspnoea—Zidovudine—acquired immunodeficiency syndrome	0.000158	0.0011	CcSEcCtD
Pomalidomide—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.000158	0.00493	CbGeAlD
Pomalidomide—TNF—Overview of nanoparticle effects—IL6—acquired immunodeficiency syndrome	0.000157	0.00881	CbGpPWpGaD
Pomalidomide—Back pain—Saquinavir—acquired immunodeficiency syndrome	0.000157	0.00109	CcSEcCtD
Pomalidomide—TNF—IL23-mediated signaling events—IL2—acquired immunodeficiency syndrome	0.000157	0.0088	CbGpPWpGaD
Pomalidomide—Confusional state—Efavirenz—acquired immunodeficiency syndrome	0.000157	0.00109	CcSEcCtD
Pomalidomide—Muscle spasms—Saquinavir—acquired immunodeficiency syndrome	0.000156	0.00108	CcSEcCtD
Pomalidomide—Anaemia—Ritonavir—acquired immunodeficiency syndrome	0.000156	0.00108	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—HLA-B—acquired immunodeficiency syndrome	0.000156	0.00873	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.000156	0.00108	CcSEcCtD
Pomalidomide—Arthralgia—Delavirdine—acquired immunodeficiency syndrome	0.000155	0.00108	CcSEcCtD
Pomalidomide—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	0.000155	0.00108	CcSEcCtD
Pomalidomide—Anxiety—Delavirdine—acquired immunodeficiency syndrome	0.000155	0.00107	CcSEcCtD
Pomalidomide—Decreased appetite—Zidovudine—acquired immunodeficiency syndrome	0.000154	0.00107	CcSEcCtD
Pomalidomide—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000153	0.00106	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000153	0.00106	CcSEcCtD
Pomalidomide—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.000153	0.00106	CcSEcCtD
Pomalidomide—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.000153	0.00106	CcSEcCtD
Pomalidomide—Thrombocytopenia—Efavirenz—acquired immunodeficiency syndrome	0.000152	0.00106	CcSEcCtD
Pomalidomide—Tremor—Saquinavir—acquired immunodeficiency syndrome	0.000152	0.00106	CcSEcCtD
Pomalidomide—Vertigo—Ritonavir—acquired immunodeficiency syndrome	0.000152	0.00105	CcSEcCtD
Pomalidomide—Pain—Zidovudine—acquired immunodeficiency syndrome	0.000152	0.00105	CcSEcCtD
Pomalidomide—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000152	0.00105	CcSEcCtD
Pomalidomide—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000151	0.00105	CcSEcCtD
Pomalidomide—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000151	0.00105	CcSEcCtD
Pomalidomide—Leukopenia—Ritonavir—acquired immunodeficiency syndrome	0.000151	0.00105	CcSEcCtD
Pomalidomide—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.000151	0.00105	CcSEcCtD
Pomalidomide—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.000151	0.00104	CcSEcCtD
Pomalidomide—Confusional state—Delavirdine—acquired immunodeficiency syndrome	0.00015	0.00104	CcSEcCtD
Pomalidomide—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.00015	0.00104	CcSEcCtD
Pomalidomide—Anaemia—Saquinavir—acquired immunodeficiency syndrome	0.00015	0.00104	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	0.00015	0.00104	CcSEcCtD
Pomalidomide—Back pain—Lamivudine—acquired immunodeficiency syndrome	0.00015	0.00104	CcSEcCtD
Pomalidomide—TNF—Vitamin B12 Metabolism—ALB—acquired immunodeficiency syndrome	0.00015	0.00839	CbGpPWpGaD
Pomalidomide—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000149	0.00104	CcSEcCtD
Pomalidomide—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000149	0.00104	CcSEcCtD
Pomalidomide—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000149	0.00103	CcSEcCtD
Pomalidomide—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.000149	0.00103	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	0.000149	0.00832	CbGpPWpGaD
Pomalidomide—Rash—Didanosine—acquired immunodeficiency syndrome	0.000148	0.00103	CcSEcCtD
Pomalidomide—Infection—Delavirdine—acquired immunodeficiency syndrome	0.000148	0.00103	CcSEcCtD
Pomalidomide—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000148	0.00103	CcSEcCtD
Pomalidomide—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000148	0.00103	CcSEcCtD
Pomalidomide—Cough—Ritonavir—acquired immunodeficiency syndrome	0.000147	0.00102	CcSEcCtD
Pomalidomide—Headache—Didanosine—acquired immunodeficiency syndrome	0.000147	0.00102	CcSEcCtD
Pomalidomide—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000147	0.00102	CcSEcCtD
Pomalidomide—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000147	0.00102	CcSEcCtD
Pomalidomide—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000146	0.00101	CcSEcCtD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—acquired immunodeficiency syndrome	0.000146	0.00818	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.000146	0.00101	CcSEcCtD
Pomalidomide—Vertigo—Saquinavir—acquired immunodeficiency syndrome	0.000146	0.00101	CcSEcCtD
Pomalidomide—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	0.000146	0.00101	CcSEcCtD
Pomalidomide—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	0.000145	0.00101	CcSEcCtD
Pomalidomide—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.000145	0.00101	CcSEcCtD
Pomalidomide—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000145	0.001	CcSEcCtD
Pomalidomide—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000145	0.001	CcSEcCtD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CSF2—acquired immunodeficiency syndrome	0.000145	0.00809	CbGpPWpGaD
Pomalidomide—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000144	0.001	CcSEcCtD
Pomalidomide—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000144	0.001	CcSEcCtD
Pomalidomide—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000144	0.000999	CcSEcCtD
Pomalidomide—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000144	0.000999	CcSEcCtD
Pomalidomide—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000144	0.000997	CcSEcCtD
Pomalidomide—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000143	0.000994	CcSEcCtD
Pomalidomide—Anaemia—Lamivudine—acquired immunodeficiency syndrome	0.000143	0.000994	CcSEcCtD
Pomalidomide—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000143	0.000993	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000143	0.00099	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000142	0.000987	CcSEcCtD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—acquired immunodeficiency syndrome	0.000142	0.00796	CbGpPWpGaD
Pomalidomide—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000142	0.000986	CcSEcCtD
Pomalidomide—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000142	0.000985	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000142	0.000984	CcSEcCtD
Pomalidomide—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000142	0.000983	CcSEcCtD
Pomalidomide—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000141	0.000977	CcSEcCtD
Pomalidomide—Pain—Indinavir—acquired immunodeficiency syndrome	0.000141	0.000977	CcSEcCtD
Pomalidomide—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000141	0.000977	CcSEcCtD
Pomalidomide—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.00014	0.000972	CcSEcCtD
Pomalidomide—TNF—Transcription factor regulation in adipogenesis—IL6—acquired immunodeficiency syndrome	0.00014	0.00784	CbGpPWpGaD
Pomalidomide—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.00014	0.000971	CcSEcCtD
Pomalidomide—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000139	0.000968	CcSEcCtD
Pomalidomide—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000139	0.000967	CcSEcCtD
Pomalidomide—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000139	0.000966	CcSEcCtD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—acquired immunodeficiency syndrome	0.000139	0.00778	CbGpPWpGaD
Pomalidomide—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.000139	0.000963	CcSEcCtD
Pomalidomide—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000139	0.000963	CcSEcCtD
Pomalidomide—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	0.000139	0.000962	CcSEcCtD
Pomalidomide—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000138	0.000959	CcSEcCtD
Pomalidomide—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000138	0.000956	CcSEcCtD
Pomalidomide—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000137	0.000953	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000137	0.000953	CcSEcCtD
Pomalidomide—TNF—Vitamin B12 Metabolism—IFNG—acquired immunodeficiency syndrome	0.000137	0.00766	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000136	0.000942	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000136	0.000941	CcSEcCtD
Pomalidomide—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000135	0.000939	CcSEcCtD
Pomalidomide—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000135	0.000938	CcSEcCtD
Pomalidomide—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000135	0.000938	CcSEcCtD
Pomalidomide—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000135	0.000937	CcSEcCtD
Pomalidomide—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	0.000135	0.000936	CcSEcCtD
Pomalidomide—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000135	0.000935	CcSEcCtD
Pomalidomide—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000135	0.000935	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000134	0.000932	CcSEcCtD
Pomalidomide—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000134	0.000931	CcSEcCtD
Pomalidomide—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000134	0.000931	CcSEcCtD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—CCL5—acquired immunodeficiency syndrome	0.000134	0.00751	CbGpPWpGaD
Pomalidomide—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000134	0.000928	CcSEcCtD
Pomalidomide—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.000134	0.000927	CcSEcCtD
Pomalidomide—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000133	0.000924	CcSEcCtD
Pomalidomide—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000133	0.000924	CcSEcCtD
Pomalidomide—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000133	0.000924	CcSEcCtD
Pomalidomide—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000133	0.000923	CcSEcCtD
Pomalidomide—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000133	0.000923	CcSEcCtD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—acquired immunodeficiency syndrome	0.000133	0.00744	CbGpPWpGaD
Pomalidomide—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000133	0.000921	CcSEcCtD
Pomalidomide—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000133	0.000921	CcSEcCtD
Pomalidomide—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000132	0.000918	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	0.000132	0.00739	CbGpPWpGaD
Pomalidomide—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.000132	0.000915	CcSEcCtD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—IFNA1—acquired immunodeficiency syndrome	0.000132	0.00738	CbGpPWpGaD
Pomalidomide—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000132	0.000914	CcSEcCtD
Pomalidomide—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000131	0.000912	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000131	0.000909	CcSEcCtD
Pomalidomide—TNF—TGF-beta Receptor Signaling—IFNG—acquired immunodeficiency syndrome	0.000131	0.00732	CbGpPWpGaD
Pomalidomide—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.00013	0.000904	CcSEcCtD
Pomalidomide—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.00013	0.000902	CcSEcCtD
Pomalidomide—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.00013	0.000902	CcSEcCtD
Pomalidomide—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	0.00013	0.0009	CcSEcCtD
Pomalidomide—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.00013	0.000899	CcSEcCtD
Pomalidomide—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000129	0.000898	CcSEcCtD
Pomalidomide—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000129	0.000894	CcSEcCtD
Pomalidomide—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000129	0.000894	CcSEcCtD
Pomalidomide—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000129	0.000893	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000129	0.000892	CcSEcCtD
Pomalidomide—Rash—Stavudine—acquired immunodeficiency syndrome	0.000129	0.000892	CcSEcCtD
Pomalidomide—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000128	0.000891	CcSEcCtD
Pomalidomide—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000128	0.000891	CcSEcCtD
Pomalidomide—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000128	0.00089	CcSEcCtD
Pomalidomide—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000128	0.000889	CcSEcCtD
Pomalidomide—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000128	0.000889	CcSEcCtD
Pomalidomide—Headache—Stavudine—acquired immunodeficiency syndrome	0.000128	0.000886	CcSEcCtD
Pomalidomide—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000128	0.000886	CcSEcCtD
Pomalidomide—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.000128	0.000885	CcSEcCtD
Pomalidomide—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000127	0.000884	CcSEcCtD
Pomalidomide—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000127	0.000884	CcSEcCtD
Pomalidomide—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000127	0.000882	CcSEcCtD
Pomalidomide—Rash—Abacavir—acquired immunodeficiency syndrome	0.000127	0.000878	CcSEcCtD
Pomalidomide—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000127	0.000878	CcSEcCtD
Pomalidomide—Headache—Abacavir—acquired immunodeficiency syndrome	0.000126	0.000873	CcSEcCtD
Pomalidomide—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000126	0.000872	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000126	0.000871	CcSEcCtD
Pomalidomide—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000125	0.00087	CcSEcCtD
Pomalidomide—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000125	0.00087	CcSEcCtD
Pomalidomide—ABCB1—brain—acquired immunodeficiency syndrome	0.000125	0.00391	CbGeAlD
Pomalidomide—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000125	0.000864	CcSEcCtD
Pomalidomide—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000124	0.00086	CcSEcCtD
Pomalidomide—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	0.000124	0.000859	CcSEcCtD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—acquired immunodeficiency syndrome	0.000124	0.00691	CbGpPWpGaD
Pomalidomide—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000123	0.000854	CcSEcCtD
Pomalidomide—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000123	0.000852	CcSEcCtD
Pomalidomide—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000123	0.000852	CcSEcCtD
Pomalidomide—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.000123	0.000852	CcSEcCtD
Pomalidomide—TNF—IL27-mediated signaling events—IL6—acquired immunodeficiency syndrome	0.000122	0.00686	CbGpPWpGaD
Pomalidomide—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000122	0.000848	CcSEcCtD
Pomalidomide—TNF—Folate Metabolism—ALB—acquired immunodeficiency syndrome	0.000122	0.00683	CbGpPWpGaD
Pomalidomide—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000121	0.000843	CcSEcCtD
Pomalidomide—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000121	0.000842	CcSEcCtD
Pomalidomide—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000121	0.000841	CcSEcCtD
Pomalidomide—ABCB1—lymph node—acquired immunodeficiency syndrome	0.000121	0.00378	CbGeAlD
Pomalidomide—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000121	0.00084	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000121	0.000838	CcSEcCtD
Pomalidomide—PTGS2—Overview of nanoparticle effects—TNF—acquired immunodeficiency syndrome	0.000121	0.00675	CbGpPWpGaD
Pomalidomide—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.00012	0.000832	CcSEcCtD
Pomalidomide—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.00012	0.000831	CcSEcCtD
Pomalidomide—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000119	0.000827	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000119	0.000825	CcSEcCtD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL6—acquired immunodeficiency syndrome	0.000119	0.00665	CbGpPWpGaD
Pomalidomide—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000119	0.000824	CcSEcCtD
Pomalidomide—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000118	0.00082	CcSEcCtD
Pomalidomide—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000118	0.00082	CcSEcCtD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—acquired immunodeficiency syndrome	0.000118	0.00661	CbGpPWpGaD
Pomalidomide—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000118	0.000817	CcSEcCtD
Pomalidomide—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000118	0.000817	CcSEcCtD
Pomalidomide—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000118	0.000817	CcSEcCtD
Pomalidomide—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000117	0.000813	CcSEcCtD
Pomalidomide—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000117	0.000809	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—IL4—acquired immunodeficiency syndrome	0.000116	0.00648	CbGpPWpGaD
Pomalidomide—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000115	0.0008	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000115	0.000799	CcSEcCtD
Pomalidomide—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000115	0.000796	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000114	0.000794	CcSEcCtD
Pomalidomide—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000114	0.000794	CcSEcCtD
Pomalidomide—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000114	0.000793	CcSEcCtD
Pomalidomide—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.000114	0.000787	CcSEcCtD
Pomalidomide—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000113	0.000786	CcSEcCtD
Pomalidomide—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000113	0.000786	CcSEcCtD
Pomalidomide—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000113	0.000782	CcSEcCtD
Pomalidomide—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000113	0.000782	CcSEcCtD
Pomalidomide—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000113	0.000781	CcSEcCtD
Pomalidomide—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000112	0.000775	CcSEcCtD
Pomalidomide—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000112	0.000775	CcSEcCtD
Pomalidomide—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000112	0.000774	CcSEcCtD
Pomalidomide—TNF—Folate Metabolism—IFNG—acquired immunodeficiency syndrome	0.000111	0.00623	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—IFNG—acquired immunodeficiency syndrome	0.000111	0.00623	CbGpPWpGaD
Pomalidomide—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000111	0.00077	CcSEcCtD
Pomalidomide—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.00011	0.000764	CcSEcCtD
Pomalidomide—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.00011	0.000763	CcSEcCtD
Pomalidomide—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.00011	0.000761	CcSEcCtD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—CXCR4—acquired immunodeficiency syndrome	0.000109	0.00613	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—CXCL12—acquired immunodeficiency syndrome	0.000109	0.00613	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.000109	0.000758	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000109	0.000757	CcSEcCtD
Pomalidomide—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000109	0.000756	CcSEcCtD
Pomalidomide—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000109	0.000756	CcSEcCtD
Pomalidomide—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000109	0.000755	CcSEcCtD
Pomalidomide—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000108	0.00075	CcSEcCtD
Pomalidomide—Pain—Lamivudine—acquired immunodeficiency syndrome	0.000108	0.00075	CcSEcCtD
Pomalidomide—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000107	0.000741	CcSEcCtD
Pomalidomide—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000107	0.000739	CcSEcCtD
Pomalidomide—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000105	0.000731	CcSEcCtD
Pomalidomide—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000105	0.00073	CcSEcCtD
Pomalidomide—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000105	0.000727	CcSEcCtD
Pomalidomide—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000105	0.000727	CcSEcCtD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—CCL5—acquired immunodeficiency syndrome	0.000105	0.00586	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000104	0.000723	CcSEcCtD
Pomalidomide—Rash—Indinavir—acquired immunodeficiency syndrome	0.000104	0.000721	CcSEcCtD
Pomalidomide—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000104	0.00072	CcSEcCtD
Pomalidomide—TNF—amb2 Integrin signaling—IL6—acquired immunodeficiency syndrome	0.000104	0.00581	CbGpPWpGaD
Pomalidomide—Headache—Indinavir—acquired immunodeficiency syndrome	0.000103	0.000716	CcSEcCtD
Pomalidomide—PTGS2—Spinal Cord Injury—CCR2—acquired immunodeficiency syndrome	0.000103	0.00578	CbGpPWpGaD
Pomalidomide—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000103	0.000714	CcSEcCtD
Pomalidomide—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000102	0.000707	CcSEcCtD
Pomalidomide—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000101	0.000704	CcSEcCtD
Pomalidomide—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.0001	0.000694	CcSEcCtD
Pomalidomide—Vomiting—Efavirenz—acquired immunodeficiency syndrome	9.9e-05	0.000687	CcSEcCtD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—IL2—acquired immunodeficiency syndrome	9.89e-05	0.00554	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—IL2—acquired immunodeficiency syndrome	9.89e-05	0.00554	CbGpPWpGaD
Pomalidomide—Asthenia—Ritonavir—acquired immunodeficiency syndrome	9.88e-05	0.000686	CcSEcCtD
Pomalidomide—Dizziness—Delavirdine—acquired immunodeficiency syndrome	9.85e-05	0.000683	CcSEcCtD
Pomalidomide—Rash—Efavirenz—acquired immunodeficiency syndrome	9.82e-05	0.000681	CcSEcCtD
Pomalidomide—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	9.81e-05	0.00068	CcSEcCtD
Pomalidomide—Nausea—Indinavir—acquired immunodeficiency syndrome	9.79e-05	0.000679	CcSEcCtD
Pomalidomide—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	9.77e-05	0.000678	CcSEcCtD
Pomalidomide—Headache—Efavirenz—acquired immunodeficiency syndrome	9.75e-05	0.000677	CcSEcCtD
Pomalidomide—Pruritus—Ritonavir—acquired immunodeficiency syndrome	9.75e-05	0.000676	CcSEcCtD
Pomalidomide—PTGS2—Overview of nanoparticle effects—IL6—acquired immunodeficiency syndrome	9.74e-05	0.00545	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—ALB—acquired immunodeficiency syndrome	9.69e-05	0.00542	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	9.64e-05	0.0054	CbGpPWpGaD
Pomalidomide—Asthenia—Saquinavir—acquired immunodeficiency syndrome	9.51e-05	0.00066	CcSEcCtD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	9.51e-05	0.00533	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—CXCL12—acquired immunodeficiency syndrome	9.48e-05	0.00531	CbGpPWpGaD
Pomalidomide—Vomiting—Delavirdine—acquired immunodeficiency syndrome	9.47e-05	0.000657	CcSEcCtD
Pomalidomide—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	9.43e-05	0.000654	CcSEcCtD
Pomalidomide—Rash—Delavirdine—acquired immunodeficiency syndrome	9.39e-05	0.000652	CcSEcCtD
Pomalidomide—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	9.38e-05	0.000651	CcSEcCtD
Pomalidomide—Pruritus—Saquinavir—acquired immunodeficiency syndrome	9.38e-05	0.000651	CcSEcCtD
Pomalidomide—Headache—Delavirdine—acquired immunodeficiency syndrome	9.33e-05	0.000647	CcSEcCtD
Pomalidomide—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	9.32e-05	0.000646	CcSEcCtD
Pomalidomide—Nausea—Efavirenz—acquired immunodeficiency syndrome	9.25e-05	0.000641	CcSEcCtD
Pomalidomide—TNF—IL23-mediated signaling events—IL6—acquired immunodeficiency syndrome	9.24e-05	0.00517	CbGpPWpGaD
Pomalidomide—Dizziness—Ritonavir—acquired immunodeficiency syndrome	9.11e-05	0.000632	CcSEcCtD
Pomalidomide—Asthenia—Lamivudine—acquired immunodeficiency syndrome	9.08e-05	0.00063	CcSEcCtD
Pomalidomide—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	9.07e-05	0.000629	CcSEcCtD
Pomalidomide—Pruritus—Lamivudine—acquired immunodeficiency syndrome	8.95e-05	0.000621	CcSEcCtD
Pomalidomide—Nausea—Delavirdine—acquired immunodeficiency syndrome	8.85e-05	0.000614	CcSEcCtD
Pomalidomide—TNF—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	8.84e-05	0.00495	CbGpPWpGaD
Pomalidomide—Dizziness—Saquinavir—acquired immunodeficiency syndrome	8.77e-05	0.000608	CcSEcCtD
Pomalidomide—Vomiting—Ritonavir—acquired immunodeficiency syndrome	8.76e-05	0.000608	CcSEcCtD
Pomalidomide—Rash—Ritonavir—acquired immunodeficiency syndrome	8.69e-05	0.000602	CcSEcCtD
Pomalidomide—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	8.68e-05	0.000602	CcSEcCtD
Pomalidomide—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	8.65e-05	0.0006	CcSEcCtD
Pomalidomide—Headache—Ritonavir—acquired immunodeficiency syndrome	8.63e-05	0.000599	CcSEcCtD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—acquired immunodeficiency syndrome	8.6e-05	0.00481	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—IL2—acquired immunodeficiency syndrome	8.57e-05	0.0048	CbGpPWpGaD
Pomalidomide—Vomiting—Saquinavir—acquired immunodeficiency syndrome	8.43e-05	0.000585	CcSEcCtD
Pomalidomide—Dizziness—Lamivudine—acquired immunodeficiency syndrome	8.36e-05	0.00058	CcSEcCtD
Pomalidomide—Rash—Saquinavir—acquired immunodeficiency syndrome	8.36e-05	0.00058	CcSEcCtD
Pomalidomide—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	8.35e-05	0.000579	CcSEcCtD
Pomalidomide—TNF—TWEAK Signaling Pathway—IL6—acquired immunodeficiency syndrome	8.35e-05	0.00467	CbGpPWpGaD
Pomalidomide—Headache—Saquinavir—acquired immunodeficiency syndrome	8.31e-05	0.000576	CcSEcCtD
Pomalidomide—TNF—Developmental Biology—ACTG1—acquired immunodeficiency syndrome	8.24e-05	0.00461	CbGpPWpGaD
Pomalidomide—Nausea—Ritonavir—acquired immunodeficiency syndrome	8.18e-05	0.000568	CcSEcCtD
Pomalidomide—Vomiting—Lamivudine—acquired immunodeficiency syndrome	8.04e-05	0.000558	CcSEcCtD
Pomalidomide—Rash—Lamivudine—acquired immunodeficiency syndrome	7.98e-05	0.000553	CcSEcCtD
Pomalidomide—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	7.97e-05	0.000553	CcSEcCtD
Pomalidomide—Headache—Lamivudine—acquired immunodeficiency syndrome	7.92e-05	0.00055	CcSEcCtD
Pomalidomide—Nausea—Saquinavir—acquired immunodeficiency syndrome	7.88e-05	0.000546	CcSEcCtD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—acquired immunodeficiency syndrome	7.64e-05	0.00428	CbGpPWpGaD
Pomalidomide—Nausea—Lamivudine—acquired immunodeficiency syndrome	7.51e-05	0.000521	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—CD40LG—acquired immunodeficiency syndrome	7.19e-05	0.00402	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL10—acquired immunodeficiency syndrome	7.19e-05	0.00402	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL4—acquired immunodeficiency syndrome	7.15e-05	0.00401	CbGpPWpGaD
Pomalidomide—TNF—Vitamin B12 Metabolism—IL6—acquired immunodeficiency syndrome	7.15e-05	0.004	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IFNG—acquired immunodeficiency syndrome	6.99e-05	0.00391	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL4—acquired immunodeficiency syndrome	6.99e-05	0.00391	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—HLA-B—acquired immunodeficiency syndrome	6.84e-05	0.00383	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	6.56e-05	0.00368	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IL2—acquired immunodeficiency syndrome	6.21e-05	0.00348	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—ALB—acquired immunodeficiency syndrome	5.99e-05	0.00336	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	5.95e-05	0.00333	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—IL6—acquired immunodeficiency syndrome	5.81e-05	0.00325	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—acquired immunodeficiency syndrome	5.56e-05	0.00311	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—CD4—acquired immunodeficiency syndrome	5.48e-05	0.00307	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	5.47e-05	0.00306	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	5.2e-05	0.00291	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	4.62e-05	0.00259	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	4.62e-05	0.00259	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—IL6—acquired immunodeficiency syndrome	4.46e-05	0.0025	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IFNG—acquired immunodeficiency syndrome	4.32e-05	0.00242	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	4.23e-05	0.00237	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—IL6—acquired immunodeficiency syndrome	4.1e-05	0.0023	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL2—acquired immunodeficiency syndrome	3.84e-05	0.00215	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	3.76e-05	0.0021	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	3.71e-05	0.00208	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IL6—acquired immunodeficiency syndrome	3.65e-05	0.00204	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	3.54e-05	0.00198	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—TAT—acquired immunodeficiency syndrome	3.44e-05	0.00192	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—IL6—acquired immunodeficiency syndrome	3.38e-05	0.00189	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	3.37e-05	0.00188	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	3.37e-05	0.00188	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—APOBEC3G—acquired immunodeficiency syndrome	3.28e-05	0.00184	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL6—acquired immunodeficiency syndrome	3.2e-05	0.00179	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—AGPS—acquired immunodeficiency syndrome	2.92e-05	0.00164	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	2.92e-05	0.00164	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	2.86e-05	0.0016	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TNF—acquired immunodeficiency syndrome	2.8e-05	0.00157	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CCNT1—acquired immunodeficiency syndrome	2.79e-05	0.00156	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	2.74e-05	0.00153	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	2.44e-05	0.00136	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL6—acquired immunodeficiency syndrome	2.26e-05	0.00126	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	2.07e-05	0.00116	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	1.95e-05	0.00109	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.9e-05	0.00107	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	1.65e-05	0.000926	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	1.5e-05	0.000841	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CXCR4—acquired immunodeficiency syndrome	1.47e-05	0.000821	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.35e-05	0.000756	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.35e-05	0.000754	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	1.28e-05	0.000715	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.16e-05	0.00065	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CCR5—acquired immunodeficiency syndrome	1e-05	0.000562	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	9.07e-06	0.000508	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	7.62e-06	0.000427	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CD4—acquired immunodeficiency syndrome	6.31e-06	0.000353	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ALB—acquired immunodeficiency syndrome	6e-06	0.000336	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	4.25e-06	0.000238	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—IL6—acquired immunodeficiency syndrome	3.41e-06	0.000191	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	3.39e-06	0.00019	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	2.62e-06	0.000147	CbGpPWpGaD
